AGXT2 metabolizes both ADMA and SDMA (MacAllister et al., 1996; Seppala et al., 2016), and lower AGXT2 activity is associated with higher risk for cardiovascular disease and increased carotid intimal medial thickness (Yoshino et al., 2014). Here, AGXT2 is linked to cardiovascular disorder.